Friday, 23 Aug 2019

You are here

RheumNow Week in Review – 26 August 2016

Dr. Jack Cush reviews news and journal reports from the past week on RheumNow.com.

  1. Japanese study 345 RA pts shows sustained high CRP levels associated with increased risk of CKD (~20%) https://t.co/VWOxuHOCDl
  2. Gout patients have a 17% increased risk of fracture (limbs & spine). Interestingly allopurinol use lowers risk http://buff.ly/2c1V2kI
  3. SPIRIT-P1 Study published in Lancet; Ixekizumab (Taltz), IL-17 inhibitor, better than Placebo, but same as Humira at 24wks in psoriatic arthritis outcomes; but Taltz superior to Humira at Psoriasis outcomes. https://t.co/mVZ0sMSHdX
  4. Hypotony (low intraocular pressure) is a sign of active, severe & usually symptomatic uveitis in Juvenile Arthritis https://t.co/qJOAWPcPpW
  5. RCT of osteoporotic vertebral fractures (< 6 wks) showed vertebroplasty twice better than placebo in reducing pain https://t.co/aIeKdXTU1C
  6. Risk factors for marginal ulcers in obesity gastric bypass surgery:Diabetes, Hx PUD, PPI & ASA use. But limited doses of. NSAIDs was not signif!cantly associated. PPI may be due to confounding by indication. https://t.co/9Ct4Xvmp2J
  7. DESIR early SpA Cohort - Structural progression is low (~5%) in early SpA; Sacroiliitis risk factors were B27, smoking & MRI SI inflammation https://t.co/MWsxlbb6lt
  8. Idiopathic Recurrent Pericarditis follows ~20% acute pericarditis; responds VERY well to IL-1 inhibition (anakinra) https://t.co/T28ggiTGyA
  9. Since FDA approval 2011, Benlystas uptake has been slow, but had $265 million in worldwide sales in 2014. https://t.co/hqViTE0PEs
  10. PsA have the same cancer & serious infx rates as non-PsA; but have more hematologic cancers & opportunistic infxns https://t.co/Mm9Ehpd19F
  11. Prior Cancer Patients May Safely Receive TNF Inhibitors or Rituximab
  12. Adalimumab Controls Non-Infectious Uveitis in VISUAL II Study
  13. Risk of Sepsis or Death Lower with Biologics in Rheumatoid Arthritis.
  14. EULAR 2016: Name that Country
Disclosures: 
The author has no conflicts of interest to disclose related to this subject

Add new comment

More Like This

RheumNow Podcast – Upadacitinib FDA Approved for RA (8.23.19)

Dr. Jack Cush reports on the news and journal reports from the past week on RheumNow.com, including: how your genetics may shape your microbiome; GERD as a risk factor for TMJ?; how can MDA-5+ dermatomyositis be any worse; new drug happenings; StillsNow.com; and more.

RheumNow Podcast – Antibiotics Increase RA Risk (8.16.19)

Dr. Jack Cush reports the news and important journal articles from the past week on RheumNow.com.

RheumNow Podcast – Tricked Up Lupus Criteria (8.9.19)

Dr. Jack Cush reviews the news and journal reports from the past week on RheumNow.com, including new SLE criteria, ULT in gout and MSU reductions, IVIG in ANCA vasculitis and non-TNF biologics outperform the TNF inhibitors.

EULAR Recommendations on Large Vessel Vasculitis

Th European League Against Rheumatism (EULAR) recommendations for the management of large vessel vasculitis (LVV) was originally published in 2009. Since then there have been new randomised clinical trials and cohort analyses leading to an update the original recommendations.

RheumNow Podcast – More Than a Spot of Tea (8.2.19)

Dr. Jack Cush reviews the journal articles and news reports from the past week on RheumNow.com: MMP-7 and Myositis-ILD; Post-surgical gout attacks; CV events and testosterone; and a Boxed warning for tofacitinib.